It has been recently reported that RB1 deletion can promote resistance to chemotherapy in prostate cancer [31, 34]; however, as the ELF1 locus is often lost in these same genomic deletions, we asked if ELF1 depletion might contribute to chemotherapy resistance. This evidence concerns the gene RB1 and prostate cancer.